PolyPid Ltd. Earnings Recaps
Q3 2025
Nov 12, 2025
PolyPid Ltd. reported significant progress in Q3 2025, highlighted by a scheduled pre-NDA meeting with the FDA for DPLEX 100, a system aimed at preventing surgical site infections, positioning the company for key commercial milestones ahead.
Key takeaways
- Scheduled pre-NDA meeting with the FDA for DPLEX 100 in early December is a critical step towards market introduction.
- Positive results from a new market access study indicate strong demand for DPLEX 100 among surgeons and hospital pharmacy directors.
- Successful completion of GMP inspection supports the company’s manufacturing readiness for both the US and European markets.
- Ongoing strategic discussions with potential US partners enhance the commercial outlook leveraging strong Phase III trial results.
- PolyPid is advancing its pipeline, indicating future growth opportunities in oncology, obesity, and diabetes.